Sermorelin Global Regulatory Status: What Women Need to Know

What Sermorelin Is and Why Its Regulatory Story Matters for Women

Sermorelin is a synthetic 29-amino-acid analog of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to secrete growth hormone (GH) through a physiologic pulse mechanism, unlike recombinant GH itself, which bypasses pituitary control entirely. That mechanistic difference is one reason clinicians and patients have found it attractive. The other reason is cost: compounded sermorelin typically runs a fraction of the price of approved recombinant GH products.

But the regulatory story behind sermorelin shapes every practical question you might have: Is it legal? Is it tested for purity? Has it ever been studied in women like you? The answers depend on which country you are in, which life stage you are at, and which pharmacy is filling your prescription.

Regulatory status is not abstract paperwork. It determines whether a product has passed standardized potency, sterility, and impurity testing; whether the labeling reflects risks that apply to your body; and whether post-market pharmacovigilance data exist at all. For a drug that acts on the hypothalamic-pituitary axis, an axis that shifts profoundly across a woman's reproductive life, those gaps carry real clinical weight.

The Core Regulatory Gap Women Face

Women were significantly under-represented in the adult sermorelin trials conducted during the 1980s and 1990s. A 1990 Walker et al. Pediatric study in Geref-treated children included girls, but the controlled adult data skew heavily male. This is consistent with the broader pattern the NIH Office of Research on Women's Health has documented: female participants were routinely excluded from or under-enrolled in GH-axis trials until well into the 1990s. Extrapolating male-derived pharmacokinetic data to women across reproductive years, perimenopause, or postmenopause introduces uncertainty that no amount of clinical enthusiasm can fully close.

FDA History: From Approval to Withdrawal

1990 Approval of Geref Diagnostic

The FDA approved sermorelin acetate (brand name Geref Diagnostic, manufactured by Serono Laboratories) in 1990 for a single, narrow indication: diagnosis of pituitary GH deficiency in children. The approval covered a one-time intravenous or subcutaneous stimulation test dose. It was not approved for chronic subcutaneous self-injection, which is how most women using compounded sermorelin today actually use it.

The approved diagnostic dose was 1 mcg/kg intravenously, administered once in a supervised clinical setting. This is a fundamentally different exposure pattern from a nightly 200 to 500 mcg subcutaneous injection sustained over weeks or months. The label's safety data, therefore, reflect a single-dose diagnostic scenario, not chronic therapeutic use.

2008 Voluntary Market Withdrawal

Serono voluntarily withdrew Geref Diagnostic from the U.S. Market in 2008. The withdrawal was not triggered by a safety signal or FDA enforcement action. It was a commercial decision, likely reflecting the narrow diagnostic market and the rise of alternative GH stimulation tests such as macimorelin (Macrilen), which received FDA approval in 2017 specifically for adult GH deficiency diagnosis. The FDA's drug discontinuation database documents the withdrawal but records no safety-based reason.

The withdrawal had an immediate regulatory consequence: sermorelin became a drug with no approved commercial product and no current sponsor maintaining post-market surveillance obligations. Any manufacturing standards, lot-release specifications, or adverse-event reporting pipelines that existed through Serono ceased to apply.

What "No Approved Product" Means Practically

When a drug's only approval is withdrawn, it does not automatically become illegal to prescribe or dispense. It becomes a drug with no FDA-approved finished product on the market. Compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act may legally compound it for individual patients under a valid prescription, provided the drug is not on the FDA's "Demonstrably Difficult to Compound" or "Withdrawn for Safety Reasons" lists. Sermorelin does not appear on either list as of this article's review date.

The FDA's 503A compounding framework means:

• No pre-market approval of individual compounded batches
• No mandatory lot-release sterility or potency testing by FDA
• Quality depends on the individual pharmacy's USP 797 compliance and state board oversight
• Adverse events are not systematically captured in a manufacturer-sponsored pharmacovigilance system

For you as a patient, this means the sermorelin vial you receive may be excellent pharmaceutical-grade product or it may have variability in concentration and sterility that an FDA-approved drug would not. Choosing an accredited PCAB (Pharmacy Compounding Accreditation Board) pharmacy is the closest analog to a quality assurance checkpoint available under the current framework.

Global Regulatory Status Outside the United States

European Medicines Agency (EMA)

No sermorelin product has ever received an EMA marketing authorization. The EMA's EPAR (European Public Assessment Report) database contains no entry for sermorelin. Individual EU member states may permit hospital-compounded preparations under national magistral or officinal frameworks, but these are country-level decisions governed by local pharmacy law, not EMA approval.

In practice, European women who seek sermorelin typically obtain it through private clinics using hospital-prepared formulations or by importing compounded product from non-EU sources, both of which carry additional legal and quality risks that vary by country.

United Kingdom

The Medicines and Healthcare products Regulatory Agency (MHRA) has no licensed sermorelin product. The MHRA's product license database does not list sermorelin as a licensed medicinal product. UK clinicians may prescribe unlicensed specials under the "named patient" pathway, but this places full prescriber responsibility for quality and safety on the individual clinician.

Canada, Australia, and Other Markets

Health Canada has not approved a commercial sermorelin product. In Australia, the Therapeutic Goods Administration (TGA) similarly has no registered sermorelin product on the ARTG (Australian Register of Therapeutic Goods). Compounding under pharmacist-only exemptions is possible in both countries but subject to the same absence of standardized batch testing that applies in the United States.

The global picture is consistent: sermorelin exists in a compounding-only space worldwide, with no jurisdiction having an approved, commercially manufactured, regularly lot-tested product available to women today.

What the Original Geref Label Said (and What It Did Not Cover)

The Geref Diagnostic prescribing information addressed a narrow diagnostic scenario. Several points are clinically relevant for women considering chronic therapeutic sermorelin use:

Indicated Population vs. Current Use

The label's indicated population was children with suspected pituitary GH deficiency, evaluated through a single stimulation test. The label provided no safety data on:

• Chronic nightly subcutaneous dosing (the most common current use pattern)
• Women of reproductive age
• Perimenopausal or postmenopausal women
• Women with PCOS, in whom GH axis dynamics differ from those in healthy controls
• Interactions with estrogen-containing contraceptives or hormone therapy

Estrogen status significantly affects GH secretion. Oral estrogen, because of hepatic first-pass effects, suppresses insulin-like growth factor 1 (IGF-1) generation and blunts GH pulsatility, meaning a woman taking oral combined contraceptives or oral estradiol HRT may have a different GH-axis response to sermorelin than a postmenopausal woman using transdermal estradiol, who may have yet a different response than a woman in her reproductive years using no exogenous hormones. Research published in the Journal of Clinical Endocrinology & Metabolism has documented these estrogen-route-dependent GH axis differences, though direct sermorelin-specific data stratified by estrogen formulation remain thin.

Adverse Events Captured on the Original Label

The Geref Diagnostic label documented adverse events from single-dose diagnostic use. Reported effects included:

• Facial flushing (most common, transient)
• Injection-site reactions
• Headache
• Nausea
• Tightness or pain in the chest (rare)

No chronic-use adverse event data (lipid changes, glucose handling, cortisol interactions, or effects on menstrual cycle regularity) appeared on the label, because chronic use was never studied under the approved indication.

Sex-Specific Physiology: How Female Hormonal Status Changes the Picture

The following framework for thinking about sermorelin across a woman's life stages does not appear in any single published guideline or manufacturer label. It synthesizes available pharmacokinetic and endocrinologic data to give you and your clinician a structured way to assess where on the risk-benefit spectrum you sit.

Reproductive Years (Approximately Ages 18 to 45)

GH secretion in premenopausal women is naturally higher than in age-matched men, owing to estrogen's stimulatory effect on pituitary somatotrophs. Women in this life stage may therefore see smaller absolute GH increments from sermorelin than men at the same dose, though the clinical significance of this difference has not been studied in controlled trials using compounded sermorelin formulations.

Menstrual cycle phase matters. GH pulsatility peaks in the late follicular phase, when estradiol is highest. If sermorelin amplifies these pulses, peak IGF-1 levels across a cycle may vary more than a single midcycle blood draw would suggest. Timing lab monitoring to a consistent cycle day (day 2 to 4 or consistently mid-luteal) is practical clinical advice that no current compounding pharmacy label specifically addresses.

Women in this group using sermorelin for body composition, recovery, or anti-aging purposes are doing so entirely off-label, without any controlled trial data showing efficacy or long-term safety in this population.

Perimenopause (Approximately Ages 45 to 55)

Perimenopause brings declining estradiol and rising FSH, alongside a well-documented fall in GH pulse amplitude and IGF-1. The Menopause Society's position on hormones and body composition acknowledges that the GH-IGF-1 axis contributes to the fat redistribution and lean mass loss seen in this life stage, though hormone therapy rather than GH-axis peptides is the standard-of-care approach.

Women in perimenopause are a plausible theoretical target for sermorelin: their GH axis is declining but the pituitary is still responsive, meaning sermorelin's mechanism (stimulating endogenous pulse release) may be more effective than in true pituitary failure. Whether this translates to clinically meaningful body composition benefits has not been studied in a randomized controlled trial in perimenopausal women.

Postmenopause

In postmenopause, oral estrogen therapy significantly suppresses IGF-1 through hepatic GH resistance. A postmenopausal woman on oral estradiol or conjugated equine estrogens who adds sermorelin may see blunted IGF-1 responses compared to a counterpart on transdermal estradiol or no HRT at all. This is pharmacologically predictable but clinically unvalidated in sermorelin-specific studies.

PCOS

Women with polycystic ovary syndrome (PCOS) have a complex GH-axis phenotype. Evidence from studies published in the Journal of Clinical Endocrinology & Metabolism suggests that lean women with PCOS may have elevated GH pulse frequency but normal IGF-1, while obese women with PCOS often show blunted GH secretion and reduced IGF-1. Adding a GHRH analog in the second group may theoretically restore more normal GH pulsatility, but no published trial has tested sermorelin specifically in PCOS.

Pregnancy, Lactation, and Contraception

Sermorelin is not approved for use in pregnancy and should be avoided.

Pregnancy Safety

No FDA pregnancy category letter was assigned to sermorelin under the old A-B-C-D-X system, and no structured reproductive toxicology program was required or completed because the drug was approved only for a one-time diagnostic test in children. Animal reproductive toxicology data are limited. Because sermorelin stimulates GH release, and because the GH-IGF-1 axis plays a direct role in fetal growth and placental function, the theoretical risks of perturbing this axis in pregnancy are non-trivial.

The FDA's Drugs@FDA resource does not contain human pregnancy safety data for sermorelin because no sponsor has conducted or submitted such studies. Absence of data is not safety.

If you are pregnant or planning pregnancy, sermorelin should be discontinued before attempting conception. There is no established washout period because the peptide has a short plasma half-life (approximately 11 to 12 minutes for the peptide itself, though downstream GH and IGF-1 effects persist longer), but no formal guidance exists. A conservative approach is to stop sermorelin at least one full menstrual cycle before attempting to conceive and to discuss timing with your prescribing clinician.

Lactation

No human data exist on sermorelin transfer into breast milk. The peptide is unlikely to survive gastrointestinal digestion intact if ingested by an infant, but the theoretical question of whether it stimulates the maternal pituitary in ways that alter prolactin-GH balance during lactation has not been studied. The NIH LactMed database contains no entry for sermorelin. Given the absence of any safety data, breastfeeding women should not use sermorelin.

Contraception Requirements

Women of reproductive age using sermorelin should use reliable contraception. This recommendation follows from the pregnancy contraindication and the lack of reproductive safety data, not from any specific teratogenicity signal. Sermorelin does not appear on the FDA's list of drugs with known teratogenicity requiring contraception labeling (such as isotretinoin or thalidomide), but the absence of teratogenicity data is not reassurance of safety.

Who This May Be Right For and Who Should Avoid It

Life Stages and Conditions Where Sermorelin May Be Considered

• Postmenopausal women with confirmed GH deficiency by stimulation testing, under endocrinologist supervision, when approved GH products are not accessible or affordable (off-label, compounded)
• Perimenopausal women with age-related GH decline who have been counseled thoroughly about the lack of controlled trial data in this population and who are not pregnant or breastfeeding

Life Stages and Conditions Where Sermorelin Should Be Avoided

• Pregnancy (see above)
• Active breastfeeding
• Women with active or history of pituitary tumors or cranial irradiation affecting the hypothalamic-pituitary axis
• Women with active malignancy (GH stimulation is a theoretical concern; The Endocrine Society's clinical practice guideline on adult GH deficiency states that GH therapy is contraindicated in active malignancy)
• Women with uncontrolled diabetes (GH promotes insulin resistance; women with PCOS and insulin resistance warrant particular caution)
• Women with untreated hypothyroidism, which blunts GH response and may produce misleading IGF-1 results

Safety Monitoring Recommended for Women Using Compounded Sermorelin

Because no standardized chronic-use safety data exist, monitoring should be individualized. A reasonable framework draws on The Endocrine Society's adult GH deficiency monitoring recommendations, adapted for the compounded sermorelin context:

• Baseline and every 6 months: IGF-1 (age- and sex-specific reference ranges apply; female reference ranges differ from male)
• Baseline and annually: Fasting glucose, HbA1c, fasting lipid panel
• At baseline: Thyroid function (TSH, free T4), because GH stimulation can unmask central hypothyroidism
• Women with PCOS: Add fasting insulin and HOMA-IR given additive insulin resistance risk
• Women on oral estrogen therapy: Expect lower IGF-1 responses; transdermal estrogen is the preferred route in women needing both HRT and GH-axis support, per data from studies in the Journal of Clinical Endocrinology & Metabolism
• Menstrual cycle tracking: Women in reproductive years should document any changes in cycle length or regularity after starting sermorelin

FDA Oversight of Compounding Pharmacies: What Actually Protects You

The FDA's 503A compounding pharmacy framework provides some but not all of the protections a commercially approved drug carries. Under 503A:

• Pharmacies must comply with USP 797 sterility standards
• Compounding must occur in response to a valid patient-specific prescription
• FDA may inspect pharmacies but does not pre-approve individual batches
• Adverse events are not systematically funneled into a manufacturer-sponsored pharmacovigilance database

The FDA Sentinel System, which monitors post-market safety of approved drugs through insurance claims and electronic health records, does not generate structured signals for compounded sermorelin because it is not a commercially approved product. This means population-level safety signals that would trigger label updates or market withdrawal for an approved drug simply do not accumulate for compounded sermorelin. Any safety information you see cited about compounded sermorelin is drawn from case reports, small clinical series, or extrapolation from studies of approved recombinant GH products, not from a functioning pharmacovigilance program.

Choosing a 503B outsourcing facility (rather than a 503A pharmacy) offers modestly higher quality assurance: 503B facilities must comply with current Good Manufacturing Practices (cGMP) and are subject to more intensive FDA inspection. However, 503B facilities cannot produce patient-specific compounded prescriptions in the same way as 503A pharmacies; their products are batch-manufactured for healthcare facilities.

A Clinician Perspective on the Evidence Gap

"The regulatory history of sermorelin is unusual because the drug left the commercial market not for safety reasons but for commercial ones, and yet it has continued to be used outside any post-market surveillance structure. Women deserve a frank conversation about what we know, which is mostly from a pediatric diagnostic trial, and what we are genuinely extrapolating." Dr. Elena Vasquez, MD, WomanRx Editorial Board, Board-Certified OB-GYN and Reproductive Endocrinologist.

This matters because the Walker et al. 1990 pediatric trial in Pediatrics that anchored the original FDA approval studied prepubertal children, not adult women with varying hormonal contexts. Referencing that study to justify chronic therapeutic sermorelin use in a 48-year-old woman entering perimenopause is a substantial extrapolation, and women deserve to hear that plainly.

Practical Steps Before Filling a Sermorelin Prescription

1. Verify your pharmacy's accreditation. Look for PCAB accreditation or confirm your pharmacy holds a 503A license in your state. Ask directly whether the batch has been tested for potency and sterility by a third-party laboratory.

2. Request a copy of the Certificate of Analysis (CoA). A reputable compounding pharmacy will provide this for each batch. It should show the measured concentration of sermorelin acetate, sterility testing results, and endotoxin levels.

3. Confirm your IGF-1 is measured against a female-specific reference range. IGF-1 reference intervals differ by sex and age. A lab using only age-adjusted norms without sex-stratification may misclassify your result.

4. Tell your prescriber about all estrogen exposure. Oral versus transdermal estrogen changes your GH-axis response. Your prescriber needs this information to interpret your IGF-1 and titrate your dose sensibly.

5. Discuss contraception explicitly if you are in your reproductive years. Document this conversation in your medical record.

Your prescriber should be able to tell you the dose, the monitoring plan, the pregnancy and lactation contraindications, and what will happen if you develop side effects, including who is responsible for reporting and how. If those answers are vague, that is a signal worth taking seriously before you start.